Conopco licenses anti-acne patch technology from Lavipharm

Lavipharm Laboratories Inc. (East Windsor, NJ) has entered into a License Agreement with Unilever subsidiary Conopco Inc. Under terms of the agreement, Lavipharm granted Conopco a license to manufacture, market, and sell products utilizing Lavipharm's proprietary anti-acne patch technology under Lavipharm's U.S. Patent No. 5,976,565 and its corresponding worldwide patents and patent applications. Conopco currently markets an anti-acne patch under the Ponds brand name.

Lavipharm Laboratories Inc. uses cutaneous biology and polymer science to develop and produce cosmetic and pharmaceutical patches, including its market-leading anti-blemish patch. The company's patch technology has also been adapted for cosmetic uses other than skin blemish treatment, including anti-wrinkle, pore cleansing, and skin care. Lavipharm's proprietary cosmetic patch allows for a controlled release of the active ingredients on the surface of the skin rather than through it.

Lavipharm's proprietary patch design

Lavipharm is a formulation, particle design company, with expertise in molecule transport.

For more information: Lavipharm Laboratories Inc., 69 Princeton-Hightstown Rd., East Windsor, NJ 08529. Tel: 609-371-6500. Fax: 609-371 6522.

Edited by Jim Pomager
Assistant Editor, Pharmaceutical Online